Paradigm Biopharmaceuticals Ltd.ASX: PAR

Independent Review Supports New iPPS ROW Trial

· Issued by Paradigm Biopharmaceuticals Ltd. via ASX

Filed with ASX · · 6 pages · English

Release

ASX RELEASE 19 November 2026 Independent Phase 3 analysis supports new ROW trial for iPPS Key Highlights • Independent analysis confirms the previously reported ROW findings: TrialKey’s exploratory analysis showed statistically significant results favoring iPPS for Weekly Average Daily Pain...

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

All Paradigm Biopharmaceuticals news releases